LU92282I2 - Telmisartan et/ou ses sels pharmacologiquement acceptables - Google Patents

Telmisartan et/ou ses sels pharmacologiquement acceptables

Info

Publication number
LU92282I2
LU92282I2 LU92282C LU92282C LU92282I2 LU 92282 I2 LU92282 I2 LU 92282I2 LU 92282 C LU92282 C LU 92282C LU 92282 C LU92282 C LU 92282C LU 92282 I2 LU92282 I2 LU 92282I2
Authority
LU
Luxembourg
Prior art keywords
telmisartan
acceptable salts
pharmacologically acceptable
pharmacologically
salts
Prior art date
Application number
LU92282C
Other languages
English (en)
Other versions
LU92282I9 (fr
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92282(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of LU92282I2 publication Critical patent/LU92282I2/fr
Publication of LU92282I9 publication Critical patent/LU92282I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92282C 2006-10-06 2013-09-19 Telmisartan et/ou ses sels pharmacologiquement acceptables LU92282I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121905A EP1908469A1 (fr) 2006-10-06 2006-10-06 Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats

Publications (2)

Publication Number Publication Date
LU92282I2 true LU92282I2 (fr) 2013-11-19
LU92282I9 LU92282I9 (fr) 2019-01-17

Family

ID=37744125

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92282C LU92282I2 (fr) 2006-10-06 2013-09-19 Telmisartan et/ou ses sels pharmacologiquement acceptables

Country Status (25)

Country Link
US (5) US8772278B2 (fr)
EP (5) EP1908469A1 (fr)
JP (5) JP5425631B2 (fr)
KR (2) KR101529541B1 (fr)
CN (6) CN105148272A (fr)
AR (1) AR063155A1 (fr)
BR (4) BR122013019534A2 (fr)
CA (1) CA2665435C (fr)
CL (2) CL2007002897A1 (fr)
CO (1) CO6180425A2 (fr)
CY (2) CY1114266T1 (fr)
DK (4) DK2420231T3 (fr)
ES (4) ES2425482T3 (fr)
HR (1) HRP20130696T1 (fr)
HU (4) HUE027399T2 (fr)
LU (1) LU92282I2 (fr)
MX (4) MX2009002340A (fr)
NL (1) NL300616I2 (fr)
NZ (3) NZ576109A (fr)
PL (4) PL2420232T3 (fr)
PT (1) PT2086535E (fr)
SI (1) SI2086535T1 (fr)
TW (3) TWI415605B (fr)
WO (1) WO2008040774A2 (fr)
ZA (1) ZA200901218B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (fr) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
WO2010097501A2 (fr) * 2009-02-26 2010-09-02 Orion Corporation Traitement combiné
EP2432452B1 (fr) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Une solution pharmaceutique à boire contenant telmisartan
CN102283832B (zh) * 2011-09-09 2013-04-10 南京正宽医药科技有限公司 一种预防或治疗高血压肥胖患者的药物组合物及用途
EP3682902A1 (fr) 2012-05-18 2020-07-22 Luoda Pharma Limited Formulation liquide
DE102012018903A1 (de) 2012-09-26 2014-03-27 Elisabeth Kurth Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) * 2015-09-28 2016-01-13 青岛云天生物技术有限公司 一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) * 2016-07-04 2020-12-16 株式会社カネカ 非ヒト動物において腎機能の低下を抑制する方法
PT3648761T (pt) * 2017-07-07 2024-06-05 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para a profilaxia ou tratamento de hipertensão em gatos
KR20220054292A (ko) * 2019-07-09 2022-05-02 베링거잉겔하임베트메디카게엠베하 개의 고혈압 치료를 위한 텔미사르탄
US20240058309A1 (en) * 2020-12-28 2024-02-22 Cured Inc. Pharmaceutical composition for treating chronic kidney disease
KR20260019532A (ko) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (fr) 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (fr) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
AU675935B2 (en) 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
CA2186606A1 (fr) 1994-03-29 1995-10-05 Edward B. Nelson Traitement de l'atherosclerose
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
AU2745199A (en) 1998-03-04 1999-09-20 Takeda Chemical Industries Ltd. Sustained-release preparation for aii antagonist, production and use thereof
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
US20030073705A1 (en) 2001-05-14 2003-04-17 Shahnaz Shahinfar Method of treatment
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
JP2005531558A (ja) * 2002-05-17 2005-10-20 ノバルティス アクチエンゲゼルシャフト 心筋梗塞の二次予防のためのアンギオテンシンＩＩ受容体ブロッカーおよびβブロッカーの組合せ
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20050272649A1 (en) * 2002-08-28 2005-12-08 Hruska Keith A Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (fr) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
WO2005123070A1 (fr) * 2004-06-09 2005-12-29 Fibrogen, Inc. Double blocage du systeme renine-angiotensine reduisant les niveaux du facteur de croissance du tissu conjonctif dans la nephropathie diabetique
CN1602960A (zh) * 2004-07-23 2005-04-06 海南国栋药物研究所有限公司 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
ME01615B (me) * 2004-11-05 2014-09-20 Boehringer Ingelheim Int Dvoslojna tableta koja sadrži telmisartan i amlodipin
CN1813707A (zh) * 2004-12-01 2006-08-09 鲁南制药集团股份有限公司 用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
EP1970053A1 (fr) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Composition pharmaceutique
EP2432452B1 (fr) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Une solution pharmaceutique à boire contenant telmisartan

Also Published As

Publication number Publication date
US20140288138A1 (en) 2014-09-25
TW201332547A (zh) 2013-08-16
HUE027399T2 (en) 2016-09-28
AR063155A1 (es) 2008-12-30
TWI539950B (zh) 2016-07-01
NZ597648A (en) 2013-05-31
HRP20130696T1 (hr) 2013-09-30
JP6151123B2 (ja) 2017-06-21
TW200831078A (en) 2008-08-01
HUS1300062I1 (hu) 2013-11-28
BRPI0718041A2 (pt) 2015-05-12
JP2016094436A (ja) 2016-05-26
US9308197B2 (en) 2016-04-12
DK2420231T3 (en) 2016-04-11
CN105148272A (zh) 2015-12-16
KR20090080954A (ko) 2009-07-27
CN114344293A (zh) 2022-04-15
LU92282I9 (fr) 2019-01-17
US9585873B2 (en) 2017-03-07
DK2420232T3 (en) 2016-03-07
EP2420231B1 (fr) 2016-01-13
NZ576109A (en) 2012-02-24
TW201402115A (zh) 2014-01-16
MX2009002340A (es) 2009-03-23
CN102512678A (zh) 2012-06-27
WO2008040774A2 (fr) 2008-04-10
US20180193317A1 (en) 2018-07-12
PL2420233T3 (pl) 2016-07-29
ZA200901218B (en) 2010-03-31
AU2007304216A1 (en) 2008-04-10
CN101522191A (zh) 2009-09-02
MX360148B (es) 2018-10-24
US20130190373A1 (en) 2013-07-25
ES2562182T3 (es) 2016-03-02
HUE027280T2 (en) 2016-09-28
EP2420233B1 (fr) 2016-01-13
JP2013216708A (ja) 2013-10-24
CN102580095B (zh) 2015-12-09
US20170128423A1 (en) 2017-05-11
CL2012001349A1 (es) 2012-10-12
EP2086535A2 (fr) 2009-08-12
JP5899165B2 (ja) 2016-04-06
US20080146543A1 (en) 2008-06-19
EP2420231A3 (fr) 2012-04-11
DK2420233T3 (en) 2016-04-11
EP2420232A3 (fr) 2012-05-02
JP5425631B2 (ja) 2014-02-26
AU2007304216B2 (en) 2013-06-13
PL2420231T3 (pl) 2016-07-29
CN101522191B (zh) 2012-05-16
ES2425482T3 (es) 2013-10-15
TWI539949B (zh) 2016-07-01
JP2017122115A (ja) 2017-07-13
MX360150B (es) 2018-10-24
KR101456151B1 (ko) 2014-11-04
EP1908469A1 (fr) 2008-04-09
US9949954B2 (en) 2018-04-24
CA2665435A1 (fr) 2008-04-10
PL2086535T3 (pl) 2013-10-31
HUS1800044I1 (hu) 2018-12-28
BR122013019533A2 (pt) 2015-07-14
PT2086535E (pt) 2013-08-22
JP2010505796A (ja) 2010-02-25
ES2565519T3 (es) 2016-04-05
KR20140088601A (ko) 2014-07-10
KR101529541B1 (ko) 2015-06-17
ES2567041T3 (es) 2016-04-19
CN109125730A (zh) 2019-01-04
DK2086535T3 (da) 2013-07-22
MX360147B (es) 2018-10-24
JP2013216709A (ja) 2013-10-24
CO6180425A2 (es) 2010-07-19
CN114344293B (zh) 2024-04-19
EP2420233A3 (fr) 2012-04-18
CY1114266T1 (el) 2015-11-04
EP2420232A2 (fr) 2012-02-22
EP2420231A2 (fr) 2012-02-22
TWI415605B (zh) 2013-11-21
BR122013019534A2 (pt) 2015-07-14
CA2665435C (fr) 2016-03-29
EP2086535B1 (fr) 2013-05-22
CY2013037I1 (el) 2015-11-04
NL300616I2 (fr) 2016-06-01
EP2420233A2 (fr) 2012-02-22
US8772278B2 (en) 2014-07-08
EP2420232B1 (fr) 2016-01-06
CY2013037I2 (el) 2015-11-04
PL2420232T3 (pl) 2016-06-30
US10357479B2 (en) 2019-07-23
WO2008040774A3 (fr) 2008-07-10
BR122013019535A2 (pt) 2015-07-14
NZ609533A (en) 2014-08-29
SI2086535T1 (sl) 2013-09-30
CL2007002897A1 (es) 2008-03-07
CN102580095A (zh) 2012-07-18
JP6337170B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
LU92282I2 (fr) Telmisartan et/ou ses sels pharmacologiquement acceptables
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
FIC20220033I1 (fi) Finerenoni sekä sen suolat, solvaatit ja suolojen solvaatit
DE502007000141D1 (de) Fräs- und Bohrmaschine
LU92635I2 (fr) Daclatasvir et leurs sels pharmaceutiquement acceptables, en particulier dichlorhydrate de daclatasvir
DK1989206T3 (da) E1-aktiveringsenzymhæmmere
BRPI0716893A2 (pt) Forma de dosagem sólida de olmesartan medoxomila e anlodipina
EP2045016A4 (fr) Broyeur
EP2014237A4 (fr) Échographe
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DE602007009899D1 (de) Sicherheitsschneidmesser
EP2092892A4 (fr) Ultrasonographe
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
DK1973775T3 (da) Bølgeenergi
DE602007002875D1 (de) Ultraschall-einspritzventil
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
DE502007001531D1 (de) Bohrhammer
BRPI0817542A2 (pt) NOVOS INIBIDORES DE sEH E SEU USO
DK2081689T3 (da) Valsemølle
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK2032260T3 (da) Rullemølle
EP1993447A4 (fr) Capteurs moléculaires à ultrasons et leurs utilisations
FI20060665A0 (fi) Poikkeavuuden havaitseminen
ITMO20060219A1 (it) Barriera di sicurezza